$71.930
-1.892 (-2.63%)收盤時
ORKA 資訊
ORKA 事件
Oruka Therapeutics Reports Positive Week 28 Results for ORKA-001
Oruka Therapeutics announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis. Key highlights: PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4; Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001; ORKA-001 maintained a favorable safety and tolerability profile through Week 28; 52-week EVERLAST-A data for all patients expected in December 2026; 16-week EVERLAST-B data expected in 4Q 2026. "These Week 28 results, with responses continuing to deepen months after the last dose, point to the incredible potential of ORKA-001," said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. "With over 70% of patients achieving completely clear skin after just two induction doses and a safety profile consistent with the IL-23 class, ORKA-001 has the potential to redefine the standard of care for psoriasis. We look forward to sharing the full 52-week data later this year."
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins Oruka from Arcutis Biotherapeutics (ARQT), where he served as executive VP and chief commercial officer.
Oruka Therapeutics Files $1B Mixed Securities Shelf
Oruka Therapeutics files $1B mixed securities shelf
Oruka CEO: ORKA-001 Enters Critical Phase
"The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward a series of important readouts," said Lawrence Klein, Chief Executive Officer of Oruka. "With EVERLAST-B now fully enrolled and a Phase 3 program for ORKA-001 on the horizon, alongside the initiation of ORCA-SPLASH in HS, we are executing on our strategy to establish ORKA-001 and ORKA-002 as potentially best-in-class options across psoriatic disease and beyond. We look forward to multiple significant clinical catalysts over the coming quarters."
Oruka Therapeutics Shares Down 8.1% to $85.69
Oruka Therapeutics is down -8.1%, or -$7.60 to $85.69.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。